About Contact Us Careers
Sign In

Cholinesterase Inhibitors Market Size & Share, by Indication (Alzheimer Disease Caused Dementia, Perkinson Disease Caused Dementia, Schizophrenia, Lewy Body Dementia, Myasthenia Gravis); Route of Administration (Oral, Intravenous, Intramuscular, Transdermal Patch); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 2416
  • Published Date: Nov 30, 2023
  • Report Format: PDF, PPT

Companies Dominating the Cholinesterase Inhibitors Landscape

top-features-companies
    • Eli Lilly and Company
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Allergan Plc.
    • Adamas Pharmaceutical Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Amneal Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Limited.
    • BioVie Inc.
    • Pfizer Inc.
    • Eisai Co., Ltd.
Browse Key Market Insights with Data Illustration:

In the News

  • February 2022: McGill University's Dementia Education Program’s new initiative was among the 15 projects that got backing from the Public Health Agency of Canada to increase concern for dementia and encourage dementia-inclusive communities. 
  • Sept. 12, 2023: Corium, LLC, a commercial-place biopharmaceutical organization leading the growth and commodification of novel neuroscience treatments, released the publication of information strengthening that ADLARITY (donepezil transdermal system) showed positive skin adequacy and coherence in a placebo-tackled trial with healthy volunteers

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2416
  • Published Date: Nov 30, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing cases of dementia caused by different diseases in elderly people will majorly drive the market growth of the cholinesterase inhibitors market.

The market size of the cholinesterase inhibitors market is expected to get a CAGR of approximately 9% over the forecast period, i.e., 2024-2036.

The major players in the market are Allergan Plc, Adamas Pharmaceutical Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Avadel Pharmaceuticals, Teva Pharmaceutical Industries Limited, BioVie Inc., Pfizer Inc., Eisai Co., Ltd., Janssen Global Services, Sanofi-Aventis U.S. LLC, Daiichi Sankyo Company, Limited, Shionogi & Co., Ltd. and Eli Lilly and Company.

The Alzheimer disease-caused dementia segment is anticipated to reap the largest market size by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying